T
he systemic inflammatory response syndrome (SIRS) represents the host response to numerous stimuli including trauma, burns, pancreatitis, transfusion reactions, and major surgery. Sepsis is defined as SIRS resulting from an infectious cause. Unfortunately, in the critically ill patient, sepsis is often difficult to diagnose as patients may already manifest SIRS from other illness. Approximately 70% of SIRS patients admitted to an intensive care unit (ICU) have a noninfectious cause. 1 However, the prompt diagnosis of sepsis is essential as early treatment is important for improving outcomes, 2, 3 and sepsis remains the leading cause of death in noncoronary intensive care units. 4 Standard diagnostic measures to identify infection include microbiologic cultures. Unfortunately, cultures can take Ͼ24 hours to obtain results and are neither sensitive nor specific. Other biologic markers have been studied as well. Procalcitonin has been considered a potential sepsis biomarker, and demonstrates prognostic capabilities. Wide spread use of procalcitonin in the ICU has been limited because of lack of specificity and variable sensitivity. 5 A recent metaanalysis confirmed the superiority of procalcitonin to C-reactive protein, but also identified its weakness as a diagnostic tool, suggesting it be used as a screening test with empiric antibiotics and further testing to accompany positive results. 6 Given the lack of a gold-standard molecular diagnosis for sepsis, there is an escalating search for biomarkers to help identify sepsis in the critically ill patient.
Recent developments in proteomics have allowed for analysis of complex protein fluids in greater detail than previously possible. Mass spectrometry has allowed for biomarker study and differentiation of complex samples in a multitude of diseases. Specifically the diagnosis of renal cell cancer, 7 breast cancer, 8 ovarian cancer, 9 and even the identification of intrauterine inflammation 10 have been suggested using mass spectrometry technologies.
This study was designed to evaluate differences in protein composition of plasma between critically ill SIRS patients who are becoming septic, as compared with that in critically ill SIRS patients who remain uninfected. Specifically, we hypothesized that the plasma protein composition of critically ill SIRS patients with sepsis would be different from plasma protein composition of phenotypically similar unin-fected patients manifesting SIRS. Furthermore, these differences will be detectable before the clinical diagnosis of sepsis.
METHODS
The Institutional Review Board of the University of Maryland School of Medicine approved this study.
As part of an ongoing study to characterize differences between sterile inflammation and sepsis, critically ill uninfected SIRS patients were prospectively evaluated for development of clinical sepsis. Patients over the age of 18 who were admitted to a trauma intensive care unit were screened. Trauma patients who met two of four standard SIRS criteria (Table 1) 11 and were clinically uninfected were enrolled. Exclusion criteria (Table 2 ) included potential immunocompromising states, administration of antibiotics for treatment, and extended prophylactic antibiotic use. Patients were divided into two groups: (1) uninfected SIRS, patients who remained uninfected for the course of the study; and (2) preseptic SIRS, SIRS patients who developed clinical sepsis during the course of the study. Sepsis diagnoses were based on the standard clinical criteria for SIRS and sepsis. 12, 13 Plasma was collected daily until ICU discharge (maximum 14 days) in the uninfected SIRS group. For the preseptic SIRS group, plasma was collected daily until the clinical diagnosis of sepsis then for a subsequent 3 days (maximum 17 days). Patient plasma was collected predominantly via a previously placed central venous catheter using a plasma preparation tube (BD Vacutainer, Franklin Lakes, NJ). Immediately after collection, samples were centrifuged at 1100ϫ g for 20 minutes, and plasma was subsequently removed by pipetting and divided into 0.5-mL aliquots. Samples were stored frozen at -70°C until analyzed.
To group patients by similar severity of disease and because preseptic patients converted to sepsis at varying time points after enrollment, all preseptic patients were retrospectively normalized using their clinical conversion to sepsis as the normalization point (T-0; Fig. 1 ). Clinical conversion time (T-0) was defined as the time a positive culture was obtained from an otherwise sterile location or direct visualization of perforated or necrotic bowel; and a clinical treatment (antibiotics and/or surgical procedure) was initiated for the infection as determined by majority consensus of an infectious disease attending, surgery attending, and a critical care attending. For the uninfected SIRS group, samples were time matched and T-0 normalized to clinically similar preseptic SIRS samples, based on demographic information, continued presence of SIRS, and elapsed time in the study. For both groups, samples were analyzed at four time points: DOE (day of study entry), samples drawn at study entry when both groups were uninfected; T-12, samples collected between 1 and 24 hours before the T-0 time point; T-36, samples collected 25 to 48 hours before T-0; and T-60, samples drawn 49 to 72 hours before T-0.
Protein profiling was performed in two experiments. Experiment 1 evaluated proteins differentially expressed at all time points tested between preseptic SIRS and uninfected SIRS in pooled plasma samples using a three-dimensional reverse phase/strong cation exchange/reverse phase liquid chromatography (LC 3 ) with electrospray ion trap mass spectrometry (MS 2 ), and spectrum counting for comparative quantitation 14 (performed by Mass Consortium Corporation, San Diego, CA). Briefly, plasma samples from 18 preseptic patients and 17 SIRS patients were pooled into 6 plasma pools (3 preseptic and 3 uninfected SIRS). Each individual pool was run at each time point. Samples were prepared by immunodepletion of abundant proteins (albumin, transferrin, haptoglobin, antitrypsin, immunoglobulin [Ig]G, and IgA) via Agilent Multiple Affinity Removal System (Agilent Technologies, Palo Alto, CA). Remaining protein was concentrated, ) is insufficient for these complex mixtures. Instead, the digest underwent a reverse-phase (RP) separation based on hydrophobicity, followed by strong-cation exchange (SCX) separation based on ion strength and then a third RP column was used to perform high resolution separation of the sample. Spectra peaks were identified and semiquantitated using Agilent Technologies Spectrum Mill MS Proteomics Workbench software (version 2.7, Agilent Technologies, Palo Alto, CA). MS/MS (MS 2 ) spectra were searched against the National Center for Biotechnology Information nonredundant protein database. The false-positive rate was estimated by autovalidating 4,294 spectra and 107 proteins by searching against a combined forward-reverse database. For proteins with at least two unique peptides, the false-positive rate was 2.8%. Spectrum counting was used for relative protein quantification. The total spectra numbers were normalized across all rounds and entries were removed if they had a distinct sum tag score less than 13. Sepsis-to-SIRS ratios were calculated using the normalized total spectra numbers. Where SIRSϾ sepsis, the ratio was calculated using 1/(sepsis/SIRS). If either number was zero, the entry was tagged SEPSISϩ or SIRSϩ as appropriate. Discovered proteins were matched to Entrez gene identification.
In experiment 2, a slightly different procedure was performed. Electrospray ionization (ESI) LTQ-FTMS (Thermo Electron, Waltham MA) mass spectrometry profiling was run on pooled plasma on both groups collected at the T-12 time point. Large proteins were removed by centrifugal ultracentrifugation using a 30-kDa cutoff Centriplus ultrafilter (Millipore, Billerica, MA). This was followed by passing samples through an SCX and C18 column, before a single round of liquid chromatography. Eleven preseptic patients were compared with 10 uninfected SIRS patients. Peaks were identified using Agilent Technologies Spectrum Mill Workbench software. The data were normalized and ratios calculated identically to the first experiment. Proteins were matched to Entrez gene identifications.
To ascertain functional and relevant biologic pathways, the list of proteins identified as differential between the preseptic and uninfected SIRS groups was uploaded as their corresponding Entrez gene identifications to the Database for Annotation, Visualization, and Integrated Discovery version 2.1 (DAVID 2.1) software available from the National Institute of Allergy and Infectious Disease (http://NAID.abcc.ncifcrf.gov). 16, 17 This allowed for annotation to biologic pathways. Statistical significance of pathways was analyzed by the Expression Analysis System Explorer (EASE) score. The EASE score, a 
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Volume 62 • Number 5modification of the Fisher-exact test, allows for the ranking of biologic pathways associated with sets of genes and identifies functional categories over-represented in a gene list relative to its representation within the genome of a given species. Significant genes are mapped to known complement and coagulation cascade (KEGG) 18, 19 and Biocarta 20 pathways.
RESULTS
For experiment 1, the patients were well matched for age and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Although APACHE II scores trended higher in the preseptic group, this difference was not significant (Table 3 ). The preseptic group did have a higher number of penetrating injuries and intra-abdominal injuries, but despite this, both Injury Severity Score (ISS) and Trauma Injury Severity Score (TRISS) were well matched between groups. Similar demographics were noted in experiment 2 (Table 4) .
In experiment 1 at DOE, 55 proteins were differential between groups: 37 were semiquantitatively greater in the preseptic group, whereas 18 were decreased. At T-60, 54 unique proteins were noted to be differential between groups (Table 5) , of which 22 were semiquantitatively greater in the sepsis group. At T-36, 27 unique proteins were noted to be differential between groups (Table 6 ), of which 10 were semiquantitatively greater in the sepsis group. At T-12, 38 unique proteins (Table 7) were noted to be differential between groups, of which 28 were semiquantitatively greater in the sepsis group. In all, accounting for proteins apparent in more than one time point, there were 71 unique proteins corresponding to unique Entrez gene identifications demonstrating significant differences between groups at the three time points before sepsis diagnosis excluding DOE.
In experiment 2, samples were run at T-12. We discovered 93 proteins corresponding to 93 unique gene identifications differential between groups at this time point (Table 8) .
Of the 71 proteins from experiment 1 and 93 from experiment 2, 30 were identical between experiments (Table  9) , 13 identical at the T-12 time point, as well as 17 found at T-12 in experiment 2 that were identical to proteins found at other time points in experiment 1. The union of unique proteins discovered by each experiment generated a total list of 134 unique proteins. To obtain an overall picture of the system changes occurring between septic and uninfected inflammation, this list was uploaded into DAVID 2.1 for analysis. Pathway analysis via EASE score demonstrated 32 of the 134 (23.5%, p ϭ 2.5 ϫ 10
Ϫ42
) mapped to the KEGG pathway: complement and coagulation cascade (Tables 10  and 11 ). Other major pathways (Biocarta) over-represented by our list include (all p Ͻ 3 ϫ 10 The Journal of TRAUMA Injury, Infection, and Critical Care
There were very few noncomplement/coagulation pathways statistically significantly represented within our group. Among the KEGG pathways, cell communication (10 proteins, 7.4%; p Ͻ 0.0001) and focal adhesion (9 proteins, 6.6%; p ϭ 0.012) were significant. In the Biocarta subset, acute myocardial infarction (4 proteins, 2.9%; p Ͻ 0.004), cells and molecules involved in local inflammatory response (4 proteins, 2.9%; p ϭ 0.011), and platelet amyloid precursor protein pathway (3 proteins, 2.2%; p ϭ 0.021) were the only other significant pathways. As DAVID v2.1 analysis compares lists to the entire human genome, we were interested in knowing the significance of our data compared with the known protein composition of plasma. The coagulation and complement pathway contains 63 proteins as listed by DAVID v2.1. The number of proteins in human plasma has been estimated to be between 1,000 and 4,000. Using a conservative estimate of 1,275, 21 our 32 proteins related to complement and coagulation pathway still yield significance via Fisher's exact test of p Ͻ 0.0001.
DISCUSSION
Using novel mass spectrometry technology, we have identified differential proteins in the plasma proteome of critically ill septic patients compared with critically ill uninfected patients manifesting SIRS. Over 20% of the proteins demonstrating differences between these two groups are related to complement and coagulation.
The innate immune system is essential for the early recognition and defense against microbial invasion. Complement activation is considered an integral component of the The Journal of TRAUMA Injury, Infection, and Critical Care innate immune system and the involvement of the complement system in our study is consistent with this concept. We have previously demonstrated activation of other components of innate immunity via gene expression profiling in similar patient populations. 22 Complement allows for elimination of invading cells and activation of the adaptive immune response by stimulating secretion of various cytokines. It has been suggested that the complement system could be a potential therapeutic target for sepsis. 23 Complement is activated by three distinct pathways. In the classical pathway, an antibody-antigen complex causes generation of C1q from C1. C1q binds to the Fc portion of the complex and activates C1r and C1s esterases. These cleave C2 and C4 forming C4b2a (C3 convertase). The alternative pathway does not involve antibodies. Instead, yeast zymogen, tissue-type plasminogen activator, and other substances such as some biomaterials allow formation of the alternative C3 convertase C3bBb. Finally, the Lectin pathway (mannose-binding pathway [MBL] ) is activated by MBL binding to carbohydrate structures on invading pathogens. The serine proteases MASP-1 and MASP-2 then cleave C2 and C4 forming the classic C3 convertase. C3 convertase cleaves C5, and formation of C5b-9 membrane attack complex ensues. We have found elements of all three pathways to be differential between sepsis and sterile inflammation.
This study emphasizes the close association between sepsis and coagulation. The understanding of coagulation and sepsis at the molecular level has demonstrated the interconnected and intertwined nature of these processes. The profibrinolytic, antithrombotic, and anti-inflammatory drug, human recombinant activated protein C has been shown to reduce mortality from sepsis. 24 In these same septic patients, markers of coagulation and inflammation were related to disease severity. 25 Tissue factor is expressed in monocytes and macrophages in response to many inflammatory insults. 26 -28 Additionally, proinflammatory cytokines cause increased expression of plasminogen activator inhibitor-1 and cause a decrease in protein C receptors. Although immune activation stimulates coagulation, the reverse is also true because various coagulation proteins such as thrombin, Factor Xa, and TF-VIIa complexes stimulate cytokine production. Activated platelets also secrete chemokines, promote neutrophil adherence, and, through CD-40, promote adhesion molecule expression on endothelium.
One strength of this study is the patient population and control groups. Instead of comparing sepsis to normal, healthy subjects, our preseptic group was compared with clinically similar critically ill patients manifesting SIRS. This allows for a better distinction between infected and uninfected SIRS in the ICU. Whereas evidence exists suggesting similar mechanisms for induction of inflammation via both infectious and noninfectious causes, 29 -31 this study demonstrated coagulation and complement differences in these patient populations. Further, using two separate methods and different pools of plasma, a large group of proteins identical between sets was identified.
Understanding the complex interactions and changes in the plasma proteome of patients becoming septic could allow for better diagnostics and therapeutics. Many of the proteins identified do not have commercially available immunoassays and therefore new assays are being developed to verify and precisely quantify results obtained with this experiment. Future studies will test these proteins as potential biomarkers for sepsis. Understanding the complex systems events leading to sepsis may yield novel therapeutic targets. Further, since a subset of proteins demonstrated differential quantitation at study entry, it may be possible to stratify critically ill patients into various categories of risk of developing sepsis immediately at admission to the ICU.
One concern regarding this study is the calculated falsepositive rate of 2.8% that may have resulted in up to four of our proteins considered false positives. However, even if all Serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 SERPIND1 Serine (or cysteine) proteinase inhibitor, clade D (heparin co-factor), member 2 SERPINF2 Serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 SERPING1 Serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 2
The Journal of TRAUMA Injury, Infection, and Critical Care four map to coagulation and protein pathways, the list would still include 28 proteins or 20% of differentially expressed proteins as members of this group and the pathway would still be highly significant. Additionally, if a significant number of false-positive proteins were present, we would expect to see a larger variance in the categories of pathways identified. The fact that the vast majority revolve around similar themes of complement and coagulation suggests a low impact of the false-positive rate. For instance, we did not find any metabolism, endocrine, or cancer pathways. Another concern was a small set of discordant findings. As experiment 1 was run as three pools per time point, there were 15 proteins at T-60 and 5 at T-12 that demonstrated differences in directional changes between pools. Despite this, an overall picture of the direction and magnitude of change was still noted for these proteins. A third concern would be the differences in mechanism of injury between groups. Among all proteins measured, there were 55 proteins significantly different at DOE. Forty-seven (85.4%) of these were also noted to be different at later time points preceding sepsis diagnosis. These 47 represent only 35% of the 134 unique proteins that were different before sepsis. Although these proteins may represent differences in mechanisms of injury, they may also suggest a protein-related predisposition to sepsis. This concept would potentially hold prognostic and/or predictive value and further study is indicated to ascertain if they are markers of a predisposition to sepsis. Specific to complement and coagulation proteins, there are 15 annotated proteins that were significant at day of study entry, in addition to the later study periods (Table 12 ). This group represented 46.9% of the 32 differentially expressed complement and coagulation proteins noted leading up to T-0. However, because the average time to T-0 was 7 days in both groups, and because APACHE II, ISS, and TRISS were well matched, those proteins demonstrating differences at the three time points before sepsis diagnosis but not at DOE, represent changes related to development of sepsis rather than differences in mechanism of injury.
CONCLUSION
This study has identified specific plasma proteomic differences between critically ill SIRS patients who subsequently develop sepsis, and clinically similar SIRS patients who remained uninfected. These differences appear as early as 3 days before the clinical diagnosis of sepsis. Complement and coagulation proteins are statistically significantly overrepresented in this set. It is possible that a subset of these proteins may be useful as biomarkers for sepsis. Future study is warranted to evaluate these proteins for their potential predictive or diagnostic role. First of all, this article agrees with the bias that I have voiced for the past 10 years, which is to say that the coagulation system and the inflammatory system are not two different systems, but rather one single system with different proteins that perform different functions.
The second one is that it is awfully hard to criticize very significantly an article that quotes your own articles.
And third, it hasn't escaped me that the recorder in this session is the senior author on the article.
Looking at the paper, there are several things that struck me: first of all, the inclusion criteria you could have included in this article simply by having a temperature of 38.1°C, with a white blood cell count of 12.1000. How many of our ICU patients don't have that?
The blood was very honestly reported as being predominately drawn from indwelling central venous catheters, or central catheters. It's well known that these catheters develop a fibrin sheath shortly after insertion. That then becomes proteinized. These proteins may reflect a very local environment and not the systemic environment. Nonetheless, it doesn't discount many of the findings. What do you think you would have found had you drawn the samples from, say, a peripheral stick, as we would with blood cultures typically, rather than a central line.
Next, how do you know which patients really were septic versus which patients had SIRS? Specifically, were all patients cultured the same, from the same sites, in the same way, or as is represented in the article-and I suspect is the case-were certain patients identified as potentially having an infection, as we do clinically, cultures drawn, and then those cultures turn positive; and then those patients are placed into the Septic rather than the SIRS group? If this is the case, then truthfully, what this is a retrospective study of prospectively collected data.
If all patients were not cultured systematically, prospectively, why not? We all know that cultures, drawn from central venous catheters, have a tendency to grow bacteria, which doesn't necessarily mean that the patient is septic. It may simply mean that the catheter is colonized. Why is it colonized? Because it developed a fibrin sheath; the fibrin sheath got proteins to adhere to it, and the bacteria stick to the proteins. Were the cultures drawn from the central venous catheters?
The next question is, since this is the American Association for the Surgery of Trauma, I was interested to note that in comparing the groups, you compared APACHE scores, but not injury severity scores. And in experiment 2-it went by a little bit quickly-100% of the patients in the SIRS group were blunt trauma patients, whereas only 45% of the patients in the Septic group were blunt trauma patients. Why did you not evaluate the patients' traumatic injuries, since they were all trauma patients?
Finally, as much a comment as a question; I guess size matters. I will applaud you as having demonstrated to me the lowest p value I've ever read in an article, which was 2.5 ϫ 10 Ϫ42 ; I guess size matters. Finally, I think the authors have gone about something very novel and something very important, and that is to identify infection at its earliest point. With all of my concerns about, were some of the SIRS patients, in fact, septic? And were some of the septic patients, in fact, colonized?
I'm not sure they've done it, but they have raised great questions, and the best studies, I think, are the ones that are the most provocative and lead to future studies.
Dr. Krishnan Raghavendran (Buffalo, New York): As I understand proteomics, one of the key integral parts of proteomics is bioinformatics. I think that your statistical calculation is far from accurate if you want to do proteomic analysis.
Just simply taking two grooves and figuring out which ones are overlapping is clearly, in my opinion, not the right way to do it, because that way, you're only looking at proteins that are expressed in one versus the other.
How do you not know whether in one category, they were really increased; and in the other category, they were really reduced? So how do you not know the significance of that?
And then any form of proteomic analysis, especially in humans, is the essence of cytokines that can be produced. So why did you not employ features such as LPS stimulation to figure out the nature of intercellular cytokines that were produced?
Dr. Mitchell J. Cohen (San Francisco, California): The first question is why were the samples not matched for injury? It seems to me that the date of entry, the differences in the protein expression or activation, date of entry should be primarily from differences in injury and not necessarily differences in their septic condition.
I know that you were matched by APACHE scores, but why not by type of injury or ISS? My second question is, what's next? I understand you pooled the samples for convenience and technology, but I'm wondering if you have run samples on specific individual patients and looked at the differences in patients based on their injury or their individual physiology?
Lastly, I'm curious if you have done any probabilistic modeling or monitoring to know whether or not you can actually predict whether patients will get septic based on early measurements of these tests?
Dr. Matthew Lissauer (Baltimore, Maryland): Dr. Owings, in terms of drawing blood for cultures, all blood cultures were drawn peripherally as that is our protocol. As for blood drawn for study purposes, the majority in both groups were drawn from central lines. Might that affect the number of complement and coagulation proteins identified? I suppose that's possible. Despite a waste being drawn, it still might influence our results. However, the majority of blood was drawn centrally in both groups, and since we were looking at differences between groups, any impact of central line biofilms should have been observed in both groups equally. As we go forward and move into more prospective work we will take that into account.
In terms of which patients were septic and which had SIRS, all patients were not cultured the same. This was, as you mentioned, a retrospective look at prospectively gathered data. Basically, we retrospectively identified a time point when the majority of 3 physicians said, "This patient is septic, start an antibiotic". We took the time of sepsis as the time they had the definable, positive culture taken. We studied plasma samples from the four time points prior to this.
If all patients were not cultured prospectively, why not? That had to do with IRB approval. We were already drawing close to our allowed limit of blood for other study purposes, so unfortunately we couldn't do that. As we gather data and are able to design more prospective studies, this is certainly something we could incorporate into their design to eliminate confounders As for the question of why such a low p value, when looking at the EASE modification of Fisher's exact test, DAVID 2.0 software compares your "buckets" of genes to the whole genome. If you go back and look at the "buckets" of proteins that are in plasma, and that has been published, there are anywhere from 1,000 to 4,000 known plasma proteins. Using a conservative estimate of 1,275 (published several years ago), performing Fisher's exact test with the number of complement and coagulation proteins found in comparison to the ratio of known complement and coagulation proteins in plasma, yields a p value of about 10 Ϫ5 or 6 .
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Dr. Raghavendran's questions of detailed biostatistical analysis/bioinformatics and LPS stimulation are interesting. This is our initial evaluation of this data. We really just wanted to determine if we could identify proteins as being different between groups. With further analysis we expect to see trends over time with some proteins starting out high in one group and decreasing over time as a patient develops sepsis and vice versa.
In terms of LPS stimulation and other basic experiments, that is real bedside back to bench translational research and that is where we want to go in the future. This was initial, clinical, translational work: bringing the bench to the bedside. Knowing what we now know, we can go back to the lab with some of these proteins, and really get a good handle on the biologic changes that take place in sepsis.
In regards to Dr. Cohen's comments about why did we match with APACHE scores and not ISS or other injury scales, the focus of this study was critically ill patients and therefore we think that controlling for physiologic derangement by APACHE was more appropriate. Controlling for anatomic derangement may be of value but was not the focus of this study. Of note when we have looked at ISS in our database, it is similar between preseptic and uninfected patients overall.
In terms of why we did not match for traumatic injuries or evaluate traumatic injuries. In experiment 2 there was a difference in mechanism of injury, and that certainly may have affected our results. The extent of impact would be speculative but since no difference was noted in experiment 1, we doubt that mechanism is a significant confounder, but will look into the question.
What's next? Again this was our initial attempt at looking at differences between critically ill SIRS patients becoming, but not yet clinically diagnosed with sepsis compared with those that remain uninfected. We identified a group of proteins that may be differential between groups. Some of them are not common proteins that you usually find or that have commercially available assays. We're developing assays for them. With that technology we'll be better able to take a look at a larger number of individual patients as opposed to groups and see if we can determine differences between groups.
Finally, in terms of probabilistic modeling or predictive value, we have not done this yet with our proteomics. However, for our genetic data, we have created some models. We are able to predict with sensitivities and specificities in the mid to high 80s whether a patient will develop sepsis, but that work is still early.
